| Literature DB >> 31806038 |
Laura Ordeix1,2, Sara Montserrat-Sangrà1, Pamela Martínez-Orellana1, Marta Baxarias1, Laia Solano-Gallego3.
Abstract
BACKGROUND: Canine leishmaniosis (CanL) caused by Leishmania infantum can have several dermatological manifestations. The type of immune response elicited against the parasite appears to be at the basis for such clinical variability. Much of the work in CanL has focused on adaptive immune response and there are scarce data on the importance of the innate immune responses. Moreover, few studies have evaluated the immunological response in the cutaneous lesions in dogs naturally infected with L. infantum and with different degrees of disease severity, and no study has compared clinically-lesioned with normal-looking skin.Entities:
Keywords: Canine; Cytokine; Gene expression; Leishmania infantum; Leishmaniosis; Skin; Toll-like receptors
Mesh:
Substances:
Year: 2019 PMID: 31806038 PMCID: PMC6894470 DOI: 10.1186/s13071-019-3827-7
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Canine reference and target immune genes used in the present study
| Assay IDa | Gene symbol | Gene name | GenBank mRNA | GenBank reference sequence | Amplicon size |
|---|---|---|---|---|---|
| Cf02625049_s1 | TLR2 | Toll-like receptor 2 | AF328930.1 | NM_001005264.2 | 69 |
| Cf02622203 g1 | TLR4 | Toll-like receptor 4 | AB080363.1 | NM_001002950.1 | 120 |
| Cf02710573_s1 | TLR7 | Toll-like receptor 7 | AB248956.1 | NM_001048124.1 | 124 |
| Cf02624265_m1 | IL-10 | Interleukin 10 | AF328930.1 | NM_001003077.1 | 83 |
| Cf02623316_m1 | IFN-γ | Interferon gamma | AF091130.1 | NM_001003174.1 | 117 |
| APG2FND | PD-L1 | Programmed dead ligand 1 | NM_001291972.1 | NM_001291972.1 | 164 |
| Cf02643820_m1 | LOC479750 | Similar to CG14980-PB | XM_536878.2 | XM_536878.2 | 78 |
| Cf02664981_m1 | SDHA | Succinate dehydrogenase complex; subunit A; flavoprotein | XM_535807.2 | DQ402985.1 | 64 |
aAll the assays are commercially available from Thermo Fisher Scientific
Clinicopathological data, antibody levels, IFN-γ production in stimulated blood and skin parasite load of sick dogs (groups A and B)
| Parameter (reference intervals and units) | Group A | Group B | ||
|---|---|---|---|---|
| UPC (< 0.5) | 0.2 ± 0.1 | 0.7 ± 0.7 | ||
| Creatinine (0.5–1.5 mg/dl) | 0.8 ± 0.1 | 0.9 ± 0.2 | ||
| Urea (21.4–59.9 mg/dl) | 43 ± 14 | 31.3 ± 7.8 | 0.037 | − 2.083 |
| Total protein (5.4–7.1 g/dl) | 5.7 ± 0.6 | 9.1 ± 2.4 | 0.0001 | − 3.686 |
| Albumin (2.6–3.3 g/dl) | 3 ± 0.4 | 2.3 ± 0.8 | ||
| Beta globulin (0.9–1.6 g/dl) | 1.3 ± 0.3 | 1.9 ± 0.6 | 0.01 | − 2.572 |
| Gamma globulin (0.3–0.8 g/dl) | 0.7 ± 0.9 | 3 ± 2.6 | 0.002 | − 3.079 |
| Abumin/globulin ratio | 1.1 ± 0.2 | 0.5 ± 0.4 | 0.004 | − 2.899 |
| Hematocrit (37–55 %) | 45.6 ± 8.5 | 33 ± 9.8 | 0.024 | − 2.251 |
| Hemoglobin (12–18 g/dl) | 15.4 ± 2.4 | 11.1 ± 3.8 | 0.032 | − 2.148 |
| 136.8 ± 196.1 | 8892.7 ± 17807.7 | < 0.0001 | − 3.887 | |
| Blood | 2046 ± 2746.6 | 713.7 ± 832.8 | ||
| Blood parasite load (parasites/ml) | 7.8 ± 10.5 | 6.7 ± 11.1 | ||
| Skin parasite load (dCq) | ||||
| Clinically-lesioned | 3.6 ± 4.4 | − 0.4 ± 4.7 | 0.043 | − 2.026 |
| Normal-looking | 6.1 ± 4 | 1.7 ± 4.5 | 0.004 | − 2.869 |
Notes: Low or negative values of dCq represent higher parasite load than elevated dCq. Differences were assessed via Mann–Whitney test
Abbreviations: UPC, urinary protein/creatinine ratio; EU, enzyme-linked immunosorbent assay units; dCq, delta-cycle threshold
Fig. 1Relative quantification of the immune genes studied. a TLR2 transcripts. b TLR4 transcripts. c TLR7 transcripts. d IL-10 transcripts. e IFN-γ transcripts. f PD-L1 transcripts. Circles and squares represent individual data of each dog. Horizontal and vertical lines represent mean and standard deviation, respectively. Solid lines with P-values: Mann-Whitney U-test; dashed lines with P-values: Wilcoxon signed-rank test. Abbreviations: A, clinically-lesioned skin and normal-looking skin from Group A (stage I-mildly affected dogs); B, skin from Group B (stage II-III-severely affected dogs); C, skin from Group C (healthy non-infected dogs). Rq, normalized relative quantification
Fig. 2Heatmap illustrating the positive (red) and negative (blue) correlations between immune gene transcripts in clinically-lesioned skin from Group A (stage I- mildly affected dogs) and Group B (stage II-III-severely affected dogs) and clinicopathological, immunological and parasitological findings (correlations with P < 0.05 are indicated by an asterisk)
Fig. 3Heatmap illustrating the positive (red) and negative (blue) correlation values between immune gene transcripts in normal-looking skin from Group A (stage I-mildly affected dogs) and Group B (stage II-III-severely affected dogs) and clinicopathological, immunological and parasitological findings (correlations with P < 0.05 are indicated by an asterisk)
Multiple logistic regression models performed with all data available that presented statistical significance
| Variables | Coefficient (β) | SE | Odds ratio | 95% CI | |||
|---|---|---|---|---|---|---|---|
| All dogs (clinically-lesioned | Intercept | − 1.99 | 0.52 | ||||
| TLR2 transcript | 0.240 | 0.060 | 6.790 | 0.009* | 1.29 | 0.62–2.73 | |
| IFN-γ transcript | 0.003 | 0.001 | 4.570 | 0.033* | 1.07 | 0.52–2.23 | |
| Group B (clinically-lesioned | Intercept | − 1.150 | 0.910 | ||||
| TLR2 transcript | 0.300 | 0.150 | 4.120 | 0.042* | 1.34 | 0.47–3.82 | |
| IL-10 transcript | − 0.260 | 0.160 | 2.790 | 0.095 | 0.78 | 0.26–2.15 | |
| IFN-γ transcript | 0.003 | 0.002 | 3.230 | 0.072 | 1.00 | 0.35–2.85 | |
| PD-L1 transcript | 0.160 | 0.110 | 2.190 | 0.139 | 1.16 | 0.40–3.29 |
Notes: Coefficient is the mathematical weightings of the explanatory variables in the equation. Intercept is a mathematical constant of the model (no clinical interpretation)
Abbreviations: CI, confidence interval; SE, standard error; group B, stage II-III-severely affected dogs
*P < 0.05